Associated Papers
CD40L Activates Platelet Integrin αIIbβ3 by Binding to the Allosteric Site (Site 2) in a KGD-Independent Manner and HIGM1 Mutations Are Clustered in the Integrin-Binding Sites of CD40L.
Takada YK et al.
Cells, 2023
CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics.
França TT et al.
Journal of Clinical Immunology, 2022
Clinical, genetic and immunological characteristics of 40 Chinese patients with CD40 ligand deficiency.
Du X et al.
Scandinavian Journal of Immunology, 2019
GESPA: classifying nsSNPs to predict disease association.
Khurana JK et al.
Bmc Bioinformatics, 2015
26206375 (PubMed )
Supplement: 12859_2015_673_MOESM2_ESM.xls › Sheet1
Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again.
Hirbod-Mobarakeh A et al.
Expert Review of Clinical Immunology, 2014
The structural basis of hyper IgM deficiency - CD40L mutations.
Thusberg J et al.
Protein Engineering, Design & Selection : Peds, 2007
Soluble CD40L activates soluble and cell-surface integrin αvβ3, α5β1, and α4β1 by binding to the allosteric ligand-binding site (site 2).
Takada YK et al.
The Journal of Biological Chemistry, 0
Select a paper to view details